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htcense.Abstract Background: It is difﬁcult to diagnose tuberculosis (TB) in dialysis patients because of
the high rate of extrapulmonary TB in these patients compared with the general population.
Recently, a new diagnostic test called QuantiFERON(QFT) has been developed and shown promise
as a diagnostic tool for active TB diseases and latent TB infection. The aim of the present study was
to analyze the performance of QuantiFERON-TB Gold in tube (QFT-G) in end stage renal disease
patients receiving hemodialysis.
Methods: QuantiFERON Gold in tube (QFT-GIT) were prospectively performed in 50 end
stage renal disease (ESRD) cases undergoing hemodialysis (HD), including 6 patients with active
TB and evaluated the utility of this test in dialysis patients.
Results: Among 50 dialysis patients, positive QFT results occurred in 10 (20%), negative QFT
results occurred in 25 (50%) and indeterminate QFT results occurred in 15 (30%). All six active
TB patients had positive QFT results, and none of the 25 patients with negative results had active
TB. Among 7 patients with a history of active TB, 2 (28.5%) had positive results. Although the
indeterminate rate was relatively high, no patient with an indeterminate result had active TB.
Among 30 cases after excluding the patients with previous TB and indeterminate results, the sensi-
tivity of the QFT is 100% (6 of 6) and the speciﬁcity is 91.6% (22 of 24 cases).ail.com (K.H. Mohamed).
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
tp://dx.doi.org/10.1016/j.ejcdt.2012.10.007
136 K.H. Mohamed et al.Conclusions: Our data suggest that the QFT test is a useful supplementary tool for the diagnosis
of active TB even in dialysis patients. Negative and indeterminate results on this test may be used to
exclude the presence of active TB.
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Tuberculosis (TB) remains a major health problem not only in
developing countries but in developed countries as well. The
incidence of TB is higher in end-stage renal disease (ESRD)
patients owing to impaired host defense mechanisms, particu-
larly immune suppression, which is more important in endemic
regions [1,2]. Diagnosis is difﬁcult and delayed since extra pul-
monary involvement is more common than isolated pulmon-
ary involvement and nonspeciﬁc symptoms mimicking
uremia are seen frequently. Uremia itself is known to cause im-
paired cellular immunity, which is the major host defense
mechanism against TB infection. Moreover, patients on
hemodialysis (HD) are at increased risk of developing active
tuberculosis after primary infection, activation of quiescent
disease, or reactivation of old TB infection. Nosocomial
transmission of TB has also been reported in patients under
long-term dialysis [3]. Diagnosis of TB in immune-compro-
mised patients and patients on HD could be difﬁcult and often
missed. This is due to vague presentation with inconclusive
chest X-rays and negative tuberculin skin tests (TST). The
TST remains the standard method for identifying TB infection
in screening of latent TB infection (LTBI) in chronic renal fail-
ure patients and in patients receiving hemodialysis. In fact,
ESRD is known to be a risk factor for skin test anergy;
although the rate of anergy is quite variable, recent reports
suggest that about 32% to 40% of HD patients are anergic
[4] A new diagnostic method, QuantiFERON-TB gold in tube
is an in vitro test for Mycobacterium (M) TB infection. It mea-
sures interferon gamma (IFN-c) secreted by T-cells which are
stimulated with mixtures of synthetic peptides including the
early secretary antigenic target-6 (ESAT-6) and culture ﬁltrate
protein 10 (CFP-10) that are speciﬁc to M. TB. After incuba-
tion of whole blood with the mixture of synthetic peptides, an
ELISA detects the release of IFN-c from lymphocytes. Be-
cause the target peptides are secreted by M. TB and Mycobac-
terium bovis, but not by strains present in the Bacille Calmette
Gue´rin (BCG) vaccine and by most nontuberculous mycobac-
teria, QFT-G may correlate better with exposure to M. TB
than the TST [5]. In this study we aimed to analyze the perfor-
mance of the QFT-G in cases with ESRD receiving hemodial-
ysis and evaluate the value of the test in the diagnosis of
tuberculosis among patients on hemodialysis.
Subjects and methods
Study population
Between June 2009 and December 2011, QFT was tested in 50
patients with end-stage renal disease on hemodialysis aged 18
or older. They were HIV negative and hospitalized for reasons
including suspected active TB, fever or inﬂammation of un-
known origin, unilateral pleural effusion or abnormal lung
shadows. Physicians decided to use the QFT depending onthe medical situation (usually suspected TB disease, fever of
unknown origin or the need to rule out TB). Patients who
underwent the QFT test were enrolled in the present study.
QuantiFERON test
Blood samples were obtained just before dialysis in haemodial-
ysis patients, The QFT test was performed according to the
manufacturer’s recommendations, and test results were evalu-
ated according to the guidelines of the Centers for Disease
Control and Prevention for using the QFT test [6] as follows:
the test consisted of a negative control (a ‘nil’ well; whole
blood without antigens or mitogen), a positive control (a
‘mitogen’ well; whole blood stimulated with the mitogen
phytohaemagglutinin) and two sample wells (whole blood
stimulated with either ESAT-6 or CFP-10). Whole-blood
specimens were incubated for 18 h (overnight) at 37 C in a
humidiﬁed atmosphere. The IFN-c level of the nil well was
considered to be the background value and was subtracted
from the values for the mitogen well and the antigen-stimu-
lated wells. The test result was considered positive, and TB
infection suspected if the IFN-c level in the sample well after
stimulation with ESAT-6 and/or CFP-10 was >0.35 IU/ml
(after subtraction of the value for the nil well) irrespective of
the result for the positive control well. The test result was
considered negative with no possibility of TB infection if the
IFN-c level was <0.35 IU/ml on both antigen wells and if
the IFN-c level of the positive Control well (after subtraction
of the value for the nil well) was >0.5 IU/ml. The test result
was considered indeterminate and impossible to interpret if
the IFN-c level was <0.35 IU/ml in both antigen wells and
<0.5 IU/ml in the positive control well, or if the IFN-c level
was below half of the negative control well in both antigen
wells and >0.7 IU/ml in the negative control well.
Tuberculin skin testing (TST)
The 5 TU (tuberculin unit) of puriﬁed protein derivative (PPD)
RT23 (Statens Serum Institute, Copenhagen, Denmark) in
0.1 ml was injected intradermally by Mantoux method and
the induration was measured between 48 and 72 h after PPD
injection by a physician. Induration of 5 mm was considered
a positive TST result.
Status of TB infection
We classiﬁed TB infection into three categories: active TB,
previous TB and non-TB. For all patients, we collected
demographic, clinical, radiologic and microbiologic data. Phy-
sicians routinely carried out complete blood counts, blood
chemistries including CRP, chest radiographs, history taking,
general physical examinations and epidemiologic surveys (self
reported history of active TB, self-reported contact with an
active case of TB, occupational history). When we suspected
Table 2 Reasons for hospital admission (No. of patients).
Fever or inﬂammation of unknown origin 10
Unilateral pleural eﬀusion 6
Pneumonia 5
Abnormal lung shadow 6
Heart failure (including ischaemic heart disease) 6
Infection (except pneumonia) 6
Initiation of dialysis 6
Bone fracture 3
Vascular access problem 2
Table 3 Results of QFT in dialysis patients.
Active TB Non-TB Previous TB Total
Positive results 6 2 2 10
Negative results 0 22 3 25
Indeterminate results 0 13 2 15
Total 6 37 7 50
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tum smear, culture, PCR, enhanced chest CT scans and en-
hanced abdominal CT scans. Depending on the situation, we
also performed pleural effusion examinations (including
smear, culture, adenosine deaminase), lymph node biopsy. Pa-
tients were ﬁnally classiﬁed as having active TB if either culture
was positive forMycobacterium tuberculosis or the experienced
physician decided that the patients suffered from TB based on
clinical ﬁndings, patient history, imaging study, histology indi-
cating mycobacterial infection (i.e. granulomatous necrosis or
identiﬁcation of acid-fast bacilli) and the patients responded
clinically and radiologically to anti-TB treatment. We classi-
ﬁed patients who had a history of TB treatment (recorded in
charts or history taking) or who had some radiological evi-
dence of TB as previous TB patients. Patients with no current
or previous active TB or treatment were classiﬁed as non-TB
patients.
Primary renal disease
Primary renal diseases were classiﬁed according to aetiological
diagnosis into six categories: diabetic nephropathy, nephro-
sclerosis, chronic glomerulonephritis, collagen disease, vasculi-
tis, and other.
Statistical analysis
We calculated proportions of positive, negative and indetermi-
nate results across active TB, non-TB and previous TB pa-
tients. All analyses were performed using computer software
(SPSS, version 10.0; SPSS, Inc; Chicago, IL).
Results
Fifty patients (35 men and 15 women; mean age 65.4 years)
underwent QFT tests. The mean duration of dialysis was
45.4 months. Characteristics of the patients are summarized
in (Table 1). Twenty-seven patients had highly suspected active
TB with symptoms including persistent fever of unknown
origin or inﬂammation, unilateral pleural effusion, pneumonia
or abnormal lung shadow. Among them, six cases (22%) of ac-
tive TB were diagnosed after admission (Table 2).
Among the 50 dialysis patients, QFT results were positive
in 10 (20%), negative in 25 (50%) and indeterminate in 15
(30%). Six (60%) of 10 patients with a positive result had ac-
tive TB. Two (20%) of these 10 patients had a history of TB
disease and 2 (20%) did not have active or previous TB. None
of the 25 patients with a negative result had active TB disease.Table 1 Demographics of study subjects.
Patients (N) 50
Age (years; mean ± SD) 65.4 ± 12
Sex (M/F) 35/15
Duration of dialysis (months) 45.4
Cause of renal disease
Diabetic nephropathy 25
Nephrosclerosis 8
Chronic glomerulonephritis 7
Collagen disease 5
Vasculitis 3
Unknown 2Twenty-two (88%) of 25 patients with negative results did not
have a history of active or previous TB, and the remaining 3
patients (12%) had a history of TB. All 15 patients (30%) with
indeterminate results showed a positive control failure on
QFT-TB results (IFN-c< 0.5 IU/ml). None of them had ac-
tive TB. Thirteen (86.7%) of 15 patients did not have any his-
tory of active or previous TB, and 2 patients (13.3%) had a
history of previous TB (Table 3). Of the 10 patients with posi-
tive QFT results, 6 had active TB. Among these 6 patients, two
had tuberculous lymphadenitis, two had tuberculous pleuritis
and two had pulmonary TB. In both pulmonary TB patients,
active TB was easily diagnosed using sputum smear, PCR and
culture. On the other hand, a detailed investigation was needed
to diagnose extra pulmonary TB in four patients with active
TB. Two of the four extrapulmonary TB cases presented as fe-
ver of unknown origin, and two showed pleural effusion,
although the cause was difﬁcult to determine. In one patient,
tuberculous lymphadenitis, this case was presented with fever
of unknown origin and was diagnosed as mediastinal tubercu-
lous lymphadenitis by enhanced chest CT and response to TB
treatment. Only one of six was TST positive. This is consistent
with the recent report that showed the lack of utility of TST in
diagnosing active TB [7]. Among the 7 patients with a history
of active TB, 2 (28.6%) had a positive result, 3 (42.8%) had a
negative result and 2 (28.6%) had an indeterminate result on
the QFT test. It is difﬁcult to interpret QFT results in patients
with previous TB or indeterminate QFT results. So, when we
excluded indeterminate results and/or previous TB, we were
left with 30 cases. Among the 30 cases after excluding the pa-
tients with previous TB or indeterminate results, the sensitivity
of the QFT is 100% (6 of 6) and the speciﬁcity is 91.7% (22 of
24 cases).
Discussion
Our ﬁndings indicate that QFT is a useful test to diagnose ac-
tive TB in dialysis patients, as all active TB patients showed
positive QFT results, and no patient with a negative or indeter-
minate result had active TB. These results are consistent with
studies done by Inoue et al., [8] and Chung et at., [9]. This
138 K.H. Mohamed et al.study focused on dialysis patients, who are likely to develop
active TB as well as extrapulmonary TB. Among the six active
TB patients in this study: four (67%) had extrapulmonary TB
(two had tuberculous lymphadenitis and two had tuberculous
pleuritis) and two (33%) had pulmonary TB. The regular
occurrence of extrapulmonary TB among TB cases in this
study supports the ﬁndings of Hussein et al., [1].
Except for six active TB cases, no active TB cases were
found among subjects with positive QFT results, even after de-
tailed investigations. However, one case who had positive QFT
results but who was initially ruled out from having active TB
developed active TB during the follow-up period. This indi-
cates that we need to rule out the existence of active TB when
QFT results are positive. Moreover, even if we cannot conﬁrm
active TB after a positive QFT test result, we should carefully
follow up these cases. On the other hand, none of the 25 pa-
tients with negative QFT results had active TB, allowing us
to use negative results of this test to rule out active TB. In
addition, cases with indeterminate results might be regarded
as negative because no cases with indeterminate results had ac-
tive TB. Considering that indeterminate results can be treated
the same as negative results, we suggest that the sensitivity of
QFT is 100% (6 of 6) and its speciﬁcity is 91.6% (22 of 24
cases). Winthrop et al., [10] tested 100 patients with ESRD
who received hemodialysis and they reported that QFT-G
and T-SPOT-TB might offer a better method for detecting
TB infection in ESRD patients. Inoue et al., [8] reported that
the sensitivity of the QFT was 100% and the speciﬁcity was
89.7% in hemodialysis patients. In our study, the positivity
of QFT-G was similar to these studies.
Our study estimated the sensitivity of QFT-IT as being
higher than the reported range in the earlier studies from high
endemic countries. The probable reasons for obtaining lower
sensitivity for interferon gamma release assay (IGRA) include
HIV coinfection, advanced disease, malnutrition, host immune
response and variation in theM. tuberculosis strain. In most of
the studies conducted, HIV positive subjects were included
[11]. HIV is the one of the major inﬂuencing factors of perfor-
mance of QFT-IT [12]. Exclusion of HIV patients in our study
may be one of the reasons for obtaining higher sensitivity for
QFT-IT in contrast to other studies.
In terms of previous TB, the percentage of positive QFT
results in patients with previously treated TB but without ac-
tive TB has been reported to be 36.6% in the general popula-
tion (n= 134) [13]. The present study showed a rate of 28.5%
(2/7) in dialysis patients. There has been no previous report
that suggests that QFT can be used to differentiate between
previous and current TB. Therefore, the high percentage of po-
sitive QFT results makes it difﬁcult to determine whether these
patients have active or previous TB.
Only a few studies on indeterminate results among dialysis
patients have been reported. The incidence of indeterminate
results ranged from 2% to 40%, and appeared to depend on
whether they were outpatients or inpatients, had primary renal
diseases and whether complications were present. Our study
showed that 30% of patients had indeterminate results, which
is consistent with previous reports [14].In conclusion, our data suggest that the QFT test is a useful
supplementary tool for the diagnosis of active TB, and that
negative results may be used to exclude active TB in dialysis
patients. Results also suggest that the QFT test is valuable in
detecting extrapulmonary TB, which can be difﬁcult to diag-
nose. In spite of the high rate of indeterminate QFT results
in our study, no patient with indeterminate results had active
TB. This might mean that we can consider indeterminate re-
sults among dialysis patients as negative results and rule out
active TB in these patients.
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